RxDoctor Payments DataLook up a doctor →

Matthew O'Steen

Interventional Cardiology · Charleston, SCNPI 1346285087

Payments from drug & device makers

$253,933in general payments, 2019–2025

Across 946 payments — averaging $268.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$218K
  • Boston Scientific$22K
  • Novartis$1K
  • Cardiovascular Systems Inc.$1K
  • Biotronik Inc.$1K
  • Johnson & Johnson$917
  • plus $10K from 50 others

What the payments were for

  • Consulting fees$5,25012%
  • Speaking & faculty fees$12,80028%
  • Travel & lodging$4,60710%
  • Food & beverage$22,34850%
  • Education$600%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$253,933 in reported general payments places this provider in the 90th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$475,359
Medicare patients
1,396
Services billed
5,715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban445$509,709
EntrestoSacubitril/Valsartan134$178,497
XareltoRivaroxaban154$153,203
Repatha SureclickEvolocumab53$46,680
JardianceEmpagliflozin32$40,821
FarxigaDapagliflozin Propanediol16$16,004
MultaqDronedarone Hcl13$13,345
NexlizetBempedoic Acid/Ezetimibe13$7,672
Ezetimibe184$6,572
Flecainide Acetate97$4,692
Metoprolol Succinate283$4,246
Nebivolol Hcl44$3,375
Diltiazem 24hr Er (Cd)Diltiazem Hcl105$3,227
Atorvastatin Calcium245$3,001
Rosuvastatin Calcium126$2,753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$579$509,709445 claims
NovartisEntresto$1,327$178,497134 claims
Johnson & JohnsonXarelto$917$153,203154 claims
Boehringer IngelheimJardiance$537$40,82132 claims
AstraZenecaFarxiga$485$16,00416 claims
Sanofi-aventis U.S. LLCMultaq$197$13,34513 claims
Esperion Therapeutics, Inc.Nexlizet$349$7,67213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →